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Immunosuppressants and inhibitors of the renin angiotensin system are major reagents 
to treat nephrotic syndrome but their clinical effects are not necessarily satisfactory. 
Injection of doxorubicin in several strains of mice causes nephrotic syndrome-like 
disorder. Zhou et al. report that PPAR expression is down-regulated in murine 
doxorubicin nephropathy and a PPAR agonist, fenofibrate, partially ameliorates the 
disorder induced likely through stabilization of nephrin expression and suppression of 




Podocyte injury plays an important role in various proteinuric disorders. Since 
podocytes in adult humans and rodents have little proliferative activity, cellular stress 
in podocytes tends to accumulate and podocyte loss cannot be recovered (1). Therefore, 
protection of podocytes in renal disorders should be a major strategy to prevent 
worsening of renal failure, especially in chronic disease, but drugs clinically available 
for that goal are not very effective. 
   Peroxisome proliferator-activated receptors (PPARs) possess various activities 
including not only enhancement of fatty acid oxidization but also suppression of 
inflammation, apoptosis and fibrosis (2). Fenofibrate is a PPAR agonist widely used to 
treat hypertriglyceridemia patients, and its use may be also beneficial for 
cardiovascular disorders. Animal studies have shown that treatment with PPAR 
ligand or transgenic overexpression of PPAR in proximal tubules can ameliorate the 
development of cisplatin- or renal ischemia/reperfusion-induced acute kidney injury and 
diabetic nephropathy (3,4). 
Doxorubicin (adriamycin or DOX) is an anthracycline class of chemotherapy reagent 
used to treat solid or hematopoietic malignancies. DOX causes glomerulosclerosis and 
tubulointerstitial injury in several selected strains in mice (5). Docosahexaenoic acid (a 
PPAR agonist) ameliorates DOX-induced apoptosis of renal tubular cells (6). Zhou et al. 
(this issue) investigated whether fenofibrate inhibits podocyte injury and proteinuria in 
DOX-induced nephropathy among two murine strains (7). A mouse strain of BALB/c is 
highly susceptible to nephrotoxic effects of DOX, while C57BL/6 mice are resistant (5). 
Using PPAR knockout (KO) mice in 129/SvJ background, which has been usually used 
in earlier studies to generate KO mice, intravenous challenge of DOX caused more 
severe renal damage in KO mice as compared to wild-type mice (7). Renal disorder in 
129/SvJ background was slightly milder, but basically similar to that in BALB/c 
background. Furthermore, fenofibrate partially suppressed the development of DOX 
nephropathy in both strains. PPAR KO mice grew up with almost normal kidneys, 
while DOX treatment reduced glomerular PPAR mRNA expression. These findings 
suggest that certain level of PPAR activity is required to maintain normal glomerular 
structure under stressed conditions. Importantly, inhibition of DOX nephropathy by 
fenofibrate was not observed in PPAR KO mice, excluding a possibility of off-target 
effects by fenofibrate. The in vivo and in vitro findings are summarized in Figure 1 (7). 
Cardiotoxicity is a major side effect of DOX in humans, whereas proteinuria or acute 
renal failure is not so common. These observations suggest the presence of modifier 
genes which affect the sensitivity of organs and animals to DOX. Continuous effort to 
identify susceptibility conferring gene in mice has recently lead to a conclusion that 
mutation in protein kinase, DNA-activated, catalytic polypeptide (Prkdc) gene and 
subsequent depletion of mitochondrial DNA in the kidney after DOX treatment are the 
mechanism of DOX nephropathy in mice (5). Prkdc gene plays an important role in DNA 
repair and maintenance of mitochondrial DNA integrity, especially in nonreplicating 
cells such as podocytes and cardiocytes.  
Diabetic nephropathy, which is usually accompanied by massive proteinuria, is 
almost like a pandemic, which acts as the leading cause of end-stage renal failure. 
Anti-proteinuric actions of fenofibrate have been reported in rodents and humans but 
the evidence is not very strong, unfortunately. Fenofibrate treatment of type 2 diabetic 
mice resulted in dramatic suppression of nephropathy but the effects appear to be 
mediated largely by normalization of hyperglycemia (8). After streptozotocin treatment 
to cause diabetes, PPAR KO mice exhibited more pronounced renal histological 
changes compared to wild-type mice at 4 months, but albuminuria in KOs were not 
larger than controls until 2 months (9). Furthermore, PPAR protein expression was 
elevated by 3-fold in diabetic mice compared to controls (9), as opposed to reduced 
expression in DOX nephropathy (7). In a large scale human trial, treatment of type 2 
diabetes patients with fenofibrate reduced albuminuria progression (10), but 
renoprotective effects of fenofibrate have not been convincingly reproduced in following 
trials. Glomerular filtration rate may be suppressed by fenofibrate through inhibition of 
vasodilatory prostaglandin synthesis (3), but an adequate correction of glomerular 
hyperfiltraion might be renoprotective in a long term, as we have learned from blockade 
of the renin-angiotensin system. 
A lot of future study has to be done to determine whether mitochondrial DNA 
damage in podocytes is a frequently-observed cause (or simply a result) of proteinuric 
disorders and whether its correction leads to preservation of renal function in human 
disorders. Furthermore, renoprotective effects of fenofibrate should be tested in large 
scale, long-term human trials whose primary endpoints are progression of proteinuria 
and renal dysfunction. 
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↑proteinuria
↑podocytes foot process effacement
↓glomerular nephrin expression
↑hyperlipidemia and hypoalbuminemia
↑glomerulosclerosis and tubulointerstitial injury












Disruption of PPAR expression






Proposed mechanism of doxurubicin-induced nephropathy in disease-susceptible 
mouse strains. 
Treatment with fenofibrate attenuates the injury, whereas PPAR knockout mice show 
more severe renal phenotypes than wild-type mice (7). Not all combinations were 
examined by Zhou et al (7). 
 
